Abstract
Sarcoidosis is a multisystem granulomatous disease often involving lungs.
Treatment response on steroids is not well studied particularly from India. We assessed this prospectively.
To assess the short-term improvement of clinical, physiological, radiological and QOL parameters on steroid therapy treatment in pulmonary sarcoidosis.
Consecutive patients newly diagnosed as pulmonary sarcoidosis by the ILD MDT were included. They received steroids as per BTS recommendations. Clinical (VAS cough score, MMRC for dyspnea, Fatigue assessment score), physiological (FVC, LV, DLCO), radiological (Obermeyer et al HRCT scoring) and QOL (Kings sarcoidosis questionnaire) parameters were assessed at baseline and after 3-4 months of therapy.
Out of 55 patients recruited, 37(67%) of them came for follow-up. Others could not come due to the COVID pandemic. At 3-4 months of treatment, the change in VAS score for cough was -8.41(CI:-11.5,-4.88, P <0.001 ) and FAS scale was -8.4(CI:-11.95,-4.88, P <0.001). Spirometry showed an increase of mean FVC from 2.29 to 2.39 (p value<0.001). The total HRCT scoring reduced from 8.14 to 5.06 (p<0.001).
Our study demonstrated significant short-term improvement in symptoms, lung functions, radiology and QOL after 3-4 months of treatment with steroids.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA715.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021